Canopy Growth Corporation

CGC Healthcare Drug Manufacturers Specialty & Generic

Canopy Growth Corporation’s revenue for fiscal 2026 (year ended March 2026) was $206.0 million, up 6.55% from fiscal 2025. In the quarter to June 2026, revenue grew 12.4%, EPS grew 87.5%, free cash flow fell 117.6% and total debt fell 18.7%, each against the same quarter a year earlier. Dividend growth for three consecutive years, operating cash flow growth for three.

0.71 0.03 −4.05%
Market cap
$311.2M
P/E
0.0×
Fwd P/E
−5.6×
Dividend yield
—
F-score
5/9
Altman Z
−13.21
Beneish M
−3.49
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(60.39%) (48.02%) (44.51%) (40.14%)
Piotroski F-Score
5 5 5 4
ROA
(32.64%) (28.56%) (25.90%) (23.54%)
ROIC
(7.54%) (8.58%) (18.00%) (17.19%)
Return on Tangible Assets
(57.79%) (45.46%) (38.24%) (36.33%)
Average Days of Receivables
35.71 42.72 46.54 52.84
Free Cash Flow per Share
(0.25) (0.18) (0.17) (0.14)
Free Cash Flow
(67.79) (62.84) (50.49) (60.22)
Other line items

Show all line items

Columns are period end dates